寶萊特(300246.SZ):腹膜透析設備獲得醫療器械註冊證
格隆匯1月12日丨寶萊特(300246.SZ)公佈,公司於近日獲得廣東藥監局頒發的《醫療器械註冊證》。產品名稱為腹膜透析設備,與腹膜透析液配套使用,適用於急慢性腎功能衰竭患者的腹膜透析治療。
寶萊特PD600腹膜透析設備是一款腹膜透析治療模式齊全的設備,搭載物聯網系統通過軟件支持可實現遠程監控,操作自動化,以及一體化的機身設計,機身輕巧,方便患者居家使用。公司研發的這款腹膜透析設備在功能與性能上,有智能語音、視頻操作引導、多設備數據收集及藍牙傳送、簡捷設計(一鍵啟動,觸摸屏操作)等,尤其是在保證該設備品質的前提下,基於當前的醫療改革形勢和患者的實際情況,很大程度上降低腹膜透析設備的成本,提高其性價比,將會最大程度上助力全國進一步推廣腹膜透析治療。
隨着國家和各地方政策對腹膜透析支持力度加大、落地以及更大範圍的推廣,將會有更多患者首先採用腹膜透析,也將很大程度上助力我國當前的醫療改革,減輕醫療機構的壓力和社會壓力。根據中國CNRDS數據:經統計,自2016年以來近5年年均複合增長率約為11.86%,截至2021年12月底,中國大陸地區在透腹膜透析患者為12.64萬人,新增膜透析患者2.37萬人。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.